Figure 6.

Administration of tabalumab to human BAFF transgenic mice leads to decreased B-cells and a reduction in non-canonical NF-κB signaling.

Notes: Tabalumab (■) or isotype control (○) was injected SC on day 0. Mice were sacrificed on days 2, 4, 8, 11, 16, and 23. (A) Splenic B-cells were enumerated by flow cytometry using B220; (B) p52 levels in the spleen were evaluated by a binding assay; (C) Western blot showing bands for p100 and p52 in splenocyte lysates; Grb2 was monitored to ensure equivalent loading of wells. * represents P-value <0.05. (•) represents an untreated non-transgenic mouse.

Abbreviations: BAFF, B-cell activating factor; SC, subcutaneously.